NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Coherus Oncology, Inc. (CHRS) Stock Analysis

Coherus Oncology, Inc. (CHRS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

CHRS

$1.02

+$0.02 (+2.00%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CHRS with… →

CHRS Key Statistics

As of Oct 21, 2026
Trading
Open
$1.01
Previous Close
$1.00
Day's Range
1.01–1.05
52-Week Range
0.97–2.62
Volume
1.27M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.99
Valuation
Market Cap
$165.32M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.25
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.25
Financials (FY)
Revenue (FY)
$42.17M+59.81%
Net Income (FY)
$168.02M+489.41%
Profit marginThe share of revenue left as profit after all costs and taxes.
−259.41%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
154.50M
1-Year Return
−41.38%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
1.18M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, CHRS closed at $1.02, −41.38% over 1 year.

Coherus Oncology, Inc. (CHRS) has a market capitalization of $165.32M.

In fiscal 2025, CHRS reported revenue of $42.17M.

CHRS Stock Return by Calendar Year

Coherus Oncology, Inc. (CHRS) 10-year return: what $10,000 became

1 year
$10,000 $5,862
−41.38%
5 years
$10,000 $612
−93.88%
10 years
$10,000 $335
−96.65%

If you had invested $10,000 in Coherus Oncology, Inc. (CHRS) 10 years ago, at the close on October 21, 2016, it would have been worth $335 at the close on October 21, 2026: −96.65% in total, −28.81% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−28.17%
2025+2.90%
2024−58.56%
2023−57.95%
2022−50.38%
2021−8.17%
2020−3.47%
2019+98.95%
2018+2.84%
2017−68.74%
2016 (partial year)−6.29%

As of October 21, 2026.

CHRS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$42.17M$168.02M398.4%
2024$26.39M$28.51M108.0%
2023$257.24M−$237.89M−92.5%
2022$211.04M−$291.75M−138.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$42.17M$28.36M−$181.13M$168.02M398.4%
2024$26.39M$17.66M−$199.65M$28.51M108.0%
2023$257.24M$98.25M−$203.20M−$237.89M−92.5%
2022$211.04M$140.96M−$256.88M−$291.75M−138.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CHRS Valuation vs Biotechnology Median

Median of 608 stocks
MetricCHRSBiotechnology medianvs median
P/S ratio3.2513.300.2x the median
Profit margin−259.41%−38.31%221.1 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 16 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Coherus Oncology, Inc. (CHRS) at $165.32M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 144 employees.

Over the past 52 weeks the price has ranged from $0.97 to $2.62. The most recent close on file for CHRS is $1.02, dated October 21, 2026. That is +$0.02 (+2.00%) against the previous close. The latest close sits 4.72% above that 52-week low.

Financial Health

In fiscal 2025, Coherus Oncology, Inc. reported revenue of $42.17M. Against the prior fiscal year total of $26.39M, that is a change of +59.81%. The same year closed with net income of $168.02M. That is +489.41% against the prior fiscal year. The reported profit margin is −259.41%. That is 221.1 percentage points below the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to −1.25.

Across the 4 fiscal years on file, revenue moves from $211.04M in 2022 to $42.17M in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 3.25. On price-to-sales that is 0.2 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Over the trailing twelve months the total return is −41.38%. Across 10 years the annualized return works out at −28.81%. The reported beta is 0.99. Annualized volatility over the trailing 10 years is 74.82%.

Growth & Income

No dividend is on file for CHRS.

Across the complete calendar years on file, 2019 returned +98.95% and 2017 returned −68.74%. Of the 9 complete calendar years on file, 3 finished higher. So far in 2026 the total return is −28.17%.

Peer Comparison

Coherus Oncology, Inc. (CHRS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Coherus Oncology, Inc. CHRS $165.32M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Coherus Oncology, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Coherus Oncology, Inc.

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. It also has a clinical collaboration agreement with Zumutor Biologics Inc. for the development of LOQTORZI with ZM0008 as a treatment for cancer patients. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.

Visit website →